Shionogi & Co., Ltd. has a beta of 0.23 ... S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis ...

Shionogi & Co., Ltd. engages in the research ... S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive ...

A recent phase 2, randomized, placebo-controlled, double-blind human challenge study conducted in a joint endeavor by Shionogi and UBE Corporation demonstrated the efficacy and safety of a novel ...

Among the viruses circulating most are COVID-19, flu and RSV. So far this season, the CDC estimates, there have been at least 24 million flu illnesses, 310,000 hospitalizations and 13,000 deaths ...

GRAND RAPIDS, Mich. — As respiratory syncytial virus (RSV) cases surge, one family's harrowing experience highlights the importance of prevention. Emily and Joey Spadafore watched helplessly as ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan, where it will be sold by licensee Shionogi. The DTx – known as ...

(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shio... (Alliance News) - hVIVO PLC on Monday said ...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone. The two ...

highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu ...